EN DE
Watch Nanoform Finland Plc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Nanoform Finland Plc (NANOFH) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Nanoform Finland Plc stock €0.18, price €0.70, that is 74.2% below the price, quality 42 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare FI · ISIN FI4000330972

NF Nanoform Finland Plc logo Thin data Nov 9, 2026

Nanoform Finland Plc

NANOFH · HE
Very expensive, weak quality

Our calculation puts a fair price 74% below what the stock costs today.

Low debt
Revenue last quarter +16% vs. a year ago.
Quality 42/100
Mixed Growth (revenue 5y +38.9 %/yr in EUR)
Fair value €0.1800 · Strongly overvalued
Negative free cash flow
Trails peers (3/8)
Narrow moat 10/100 · thin data
Thin data
Watch Nanoform Finland Plc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€8.10 €0.4200 Fair Value €0.1800 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range €0.4200 – €8.10 · fair‑value band €0.1200 – €0.2200 · the €0.6990 price screens above the €0.1800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Nanoform Finland in your weekly email

Every Wednesday you see whether Nanoform Finland is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States.

Show moreShow less

The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) nanoparticles directly from solution; biological nanoforming technology; and dosage forms of Nanoparticles.

It also offers STARMAP, an AI platform predicts the performance of your molecule in Nanoform's technology. The company was founded in 2008 and is headquartered in Helsinki, Finland.

Stock analysis

Nanoform Finland Plc (NANOFH) currently trades at €0.6990, while our model-based Fair Value estimate is €0.1800, 74% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: €0.1200 (bear) to €0.2200 (bull), the price of €0.6990 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Nanoform Finland Plc reported revenue of €3.5M in FY2025 versus €2.0M in FY2021, a compound +16.1%/yr. Reported net income was −€17.9M in FY2025.

Key figures

Market cap €59.9M Micro · P/S ratio 10.5 · EPS (TTM) €−0.1700 · Return on equity −32.1% · Return on assets (EBIT) −29.0% (5-year average) · Operating margin −477% · Revenue (TTM) €5.5M · Revenue growth (YoY) +16.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 41% below its 52-week high and 66% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −74%, NANOFH screens richer than that median.

Fair Value models

Bear €0.1200 Fair Value €0.1800 Bull €0.2200
Price €0.6990 · Downside -74.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) €0.1200 €0.1800 €0.2200 55
All 1 models by family
Asset-Based
NCAV (Graham) €0.1200 €0.1800 €0.2200 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 62
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 36
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 18
Distance to the 52-week high, does not count
New shares 63
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+27.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.9%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+64.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,828.2% (2020) → −627.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

NANOFH screens overvalued: fair value 74% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Nanoform Finland Plc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 42 · Below median
Fair Value upside −74.2% · Bottom 25%
Profitability
Return on assets −33.2% · Below median
Growth and dividend
Revenue growth (quarter YoY) 16.2% · Above median
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.40× · Cheaper than median
P/S (12 months) 10.84× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)81 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)99 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs NANOFH
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs NANOFH
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs NANOFH
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs NANOFH
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs NANOFH
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs NANOFH
argenx SE ARGX $927.21 $908.40 −2% vs NANOFH
CSL Limited CSL A$200.77 A$183.04 −9% vs NANOFH
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs NANOFH
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs NANOFH

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nanoform Finland Plc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Nanoform Finland Plc Fair Value". https://www.fairvalue-calculator.com/stock/NANOFH

Frequently asked questions

Is Nanoform Finland Plc (NANOFH) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of €0.1800 versus a price of €0.6990, about 74% lower (overvalued).
What is the fair value of NANOFH?
Our model-based fair value for Nanoform Finland Plc is €0.1800 (as of Nov 9, 2026), built from audited fundamentals. The current price: €0.6990.
What is the quality score of NANOFH?
Nanoform Finland Plc has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nanoform Finland Plc (NANOFH)?
Our model-based price target is the fair value of €0.1800 (as of Nov 9, 2026) from 1 valuation models. Cautious scenario €0.1200, optimistic scenario €0.2200. It is a calculation from audited fundamentals, not an analyst target.
What is the Nanoform Finland Plc stock forecast for 2026?
Our models put fair value at €0.1800, about 74% lower versus a price of €0.6990 (overvalued). Cautious scenario €0.1200, optimistic scenario €0.2200. The calculation is refreshed regularly with new filings.
What is the revenue of Nanoform Finland Plc (NANOFH)?
Nanoform Finland Plc reported trailing-twelve-month revenue of about €5.5M (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Nanoform Finland Plc (NANOFH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nanoform Finland Plc it is €0.1800 per share (as of Nov 9, 2026), against a price of €0.6990. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Nanoform Finland Plc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, NANOFH trades above its calculated fair value: price €0.6990, fair value €0.1800, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NANOFH?
No. The price is what the market pays today (€0.6990); the fair value is what the company's own numbers justify (€0.1800). For Nanoform Finland Plc the two are €0.5190 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nanoform Finland Plc worth?
The market values Nanoform Finland Plc at about €59.9M (market capitalisation, as of Nov 9, 2026). Per share that is €0.6990; our models calculate a fair value of €0.1800 per share.
What do the bullish and bearish scenarios say about NANOFH?
Our models span a range for Nanoform Finland Plc: cautious scenario €0.1200, base €0.1800, optimistic €0.2200 per share (as of Nov 9, 2026, price €0.6990). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Nanoform Finland Plc (NANOFH)?
Balance-sheet figures for Nanoform Finland Plc (as of Nov 9, 2026): return on equity −32.1%, debt of 0.02 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is NANOFH from its 52-week high?
Nanoform Finland Plc trades at €0.6990, about 41% below its 52-week high of €1.18 and 66% above the low of €0.4200 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €0.1800 is for.
Which stocks are comparable to Nanoform Finland Plc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nanoform Finland Plc stock attractive at the current price?
The data as of Nov 9, 2026: price €0.6990, calculated fair value €0.1800 (−74%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NANOFH calculated?
We run Nanoform Finland Plc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of €0.1800 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Nanoform Finland Plc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nanoform Finland Plc (NANOFH)?
The closing price on Nov 6, 2026 was €0.6990. Our model-based fair value is €0.1800, about 74% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nanoform Finland Plc right now?
The price sits above even our optimistic bull case (€0.2200). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (€0.1200 to €0.2200) leaves room in how you read the outcome.

Key figures of Nanoform Finland Plc

How large is the market capitalisation of Nanoform Finland Plc (NANOFH)?
The market capitalisation of Nanoform Finland Plc is €59.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nanoform Finland Plc (NANOFH)?
The price-to-sales ratio of Nanoform Finland Plc is 10.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nanoform Finland Plc (NANOFH)?
Earnings per share at Nanoform Finland Plc are €−0.1700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Nanoform Finland Plc (NANOFH)?
The return on equity (ROE) of Nanoform Finland Plc is −32.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nanoform Finland Plc (NANOFH)?
On an EBIT basis the return on assets of Nanoform Finland Plc is −29.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nanoform Finland Plc (NANOFH)?
The operating margin of Nanoform Finland Plc is −477% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nanoform Finland Plc (NANOFH)?
Revenue at Nanoform Finland Plc is growing +16.2% versus a year earlier (3y avg +0.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Nanoform Finland Plc (NANOFH) generate?
The free cash flow of Nanoform Finland Plc is −€18.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Nanoform Finland Plc (NANOFH) hold?
Nanoform Finland Plc holds more cash than debt, €13.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Nanoform Finland Plc in the live analysis

One click puts Nanoform Finland Plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.